Dose-Response Relationship of Epirubicin in the Treatment of Postmenopausal Patients with Metastatic Breast Cancer: A Randomized Study of Epirubicin at Four Different Dose Levels Performed by the Danish Breast Cancer Cooperative Group

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1146-1155

  Bastholt, Lars ^a   Dalmark, Mads ^b   Gjedde, Susanne B ^b   Pfeiffer, Per ^b   Pedersen, Dorte ^b   Sandberg, Erik ^b   Kjær, Mogens ^b   Mouridsen, Henning T ^b   Rose, Carsten ^b   Nielsen, Ole S ^b   Jakobsen, Preben ^b   Bentzen, Søren M ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; METOCLOPRAMIDE; METOPIMAZINE; PREDNISOLONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029966673     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1146     Document Type: Article

References (46)

1. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
2. Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233-245, 1966
3. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
4. Mouridsen HT: New cytotoxic drugs in treatment of breast cancer. Acta Oncol 29:343-347, 1990
5. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO, 1979
6. Deesen PE, Leyland-Jones B: Sensitive and specific determination of the new anthracycline analog 4′-epirubicin and its metabolites by high pressure liquid chromatography. Drug Metab Dispos, 12:9-13, 1984
7. Jakobsen P, Steiness E, Bastholt L, et al: Multiple dose pharmacokinetics of epirubicin at four different dose levels. Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 28:63-68, 1991
8. Jakobsen P, Bastholt L, Dalmark M, et al: A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28:465-469, 1991
9. Cox DR: Regression models and life tables. J Stat Soc 34:187-220, 1972
10. Bastholt L, Dalmark M, Gjedde S, et al: Epirubicin at four different dose levels in metastatic breast cancer. A randomized trial. Proc Am Soc Clin Oncol 11:56, 1992 (abstr)
11. Mouridsen HT, Rose C: Values and limitations of current criteria for objective response in advanced breast cancer, in Cavalli F (ed): Endocrine Therapy of Breast Cancer II. Berlin, Germany, Springer Verlag, 1987, pp 41-46
12. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
13. Henderson IC, Hayes DF, Gelman R: Dose response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
14. Scheulen ME, Miller AA, Niederle N, et al: Clinical pharmacology of weekly low-dose epirubicin. Proc Am Assoc Cancer Res 26:153, 1985 (abstr)
15. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two dose levels of Adriamycin in the primary treatment of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987
16. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
17. Creech RH, Catalano RB, Hopson RC: A comparison of standard dose Adriamycin and low dose Adriamycin as primary chemotherapy for metastatic breast cancer. Proc Am Assoc Cancer Res 21:142, 1980 (abstr)
18. Ebbs SR, Saunders JA, Graham H, et al: A randomised trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 28, 6:887-892, 1989
19. Hortobagyi GN, Bodey GP, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354-364, 1987
20. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
21. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the relevance of epirubicin dose intensity in combination with a fixed dose of cyclophosphamide in metastatic breast cancer (MBC). Proc Eur Soc Med Oncol 5:26, 1994 (suppl 8, abstr)
22. Focan C, Andrien JM, Closon MTh, et al: Dose-response relationship of Epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 11, 7:1253-1263, 1993
23. Blomqvist C, Elomaa I, Rissanen P, et al: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 11:467-473, 1993
24. Robert J: Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45:20-30, 1993 (suppl 2)
25. Plosker GL, Faulds D: Epirubicin. A review of its pharmocodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45:788-856, 1993
26. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A:527-531, 1993
27. Bezwoda WR, Dansey R, Seymour L: High-dose 4′-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: Achievement of second responses. Oncology 47:4-8, 1990
28. Falkson G, Gelman RS, Pretorius FJ: Age as a prognostic factor in recurrent breast cancer. J Clin Oncol 4:663-671, 1986
29. Cold S, Jensen NV, Brincker H, et al: The influence of chemotherapy on survival after recurrence in breast cancer. A population-based study of patients treated in the 1950's, 1960's. and 1970's. Eur J Cancer 29A:1146-1152, 1993
30. Madsen EL, Andersson M, Mouridsen HT, et al: A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in disseminated breast cancer. Proceedings of the Fifth European Organization for Research and Treatment of Cancer Breast Cancer Working Conference, Leuven, Belgium, September 1991, p 5 (abstr)
31. Pfeiffer P, Cold S, Rose C: Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use? Acta Oncol 31:219-224, 1992
32. Muss HB, White DR, Richards F, et al: Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42:2141-2148, 1978
33. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
34. Clark GM, Sledge GW, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987
35. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979
36. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
37. Havsteen H, Brynjolf I, Svahn T, et al: Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer Chemother Pharmacol 23:101-104, 1989
38. Dardir MD, Ferrans VJ, Mikhael YS, et al: Cardiac morphologic and functional changes by epirubicin chemotherapy. J Clin Oncol 7:947-958, 1989
39. Nielsen D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990
40. Blum RH, Carter SK: Adriamycin - A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259, 1974
41. Kavanagh JJ, Yeung KY, Savaraj N, et al: Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin. Eur J Cancer Clin Oncol 21:1187-1189, 1985
42. Robert J, Illiadis A, Hoerni B, et al: Pharmacokinetics of Adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18:739-745, 1982
43. Preisler HD, Gessner T, Azarnia N, et al: Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12:125-130, 1984
44. Kerr DJ, Morrison GJ, Cassidy J, et al: Plasma epirubicin estimation as a predictor of response in breast cancer. Br J Cancer 58:244, 1988
45. Eksborg S, Hardell L, Bengtsson N-O, et al: Epirubicin as a single agent therapy for the treatment of breast cancer - A pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 9:75-80, 1992
46. Hu OYP, Chang SP, Jame JM, et al: Pharmacokinetics and pharmacodynamic studies with 4-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 24:332-337, 1989